vialaudit

affiliate disclosure · we earn commission on some vendor links. audits, scores, and rankings are independent — vendors do not pay for placement. read more →

NEWS · 9 MIN·UPDATED 2026-11-19·BY ELI WHITMER

PT-141 lab results: what 33 public certificates show

33 public PT-141 (bremelanotide) lab results: median fill 109.9% of label, two under 90%, median purity 99.88%, no fails. Plus Vyleesi and the FDA letters.

QUICK ANSWER

PT-141 is bremelanotide, a cyclic seven-amino-acid melanocortin receptor agonist. It is the active ingredient of Vyleesi, which FDA approved on 21 June 2019 under NDA 210557 for premenopausal women with acquired, generalized hypoactive sexual desire disorder. A vial sold as "research PT-141" is not that approved product, and all five FDA warning letters dated 24 August 2026 named PT-141 listings. On the public lab record the vials mostly test over label: across 33 results from 26 client names, the median vial held 109.9% of its 10 mg label and median purity was 99.88%. None was graded a fail. Two results came in under 90% of label, both on certificates the vendors published themselves. We tested none of these vials ourselves.

PT-141 is bremelanotide, the active ingredient of an FDA-approved drug. It is also one of the most-listed vials in the research-peptide trade. On the public lab record those vials test mostly over label: 33 results from 26 client names, median fill 109.9% of a 10 mg label, median purity 99.88%, 0 graded a fail. Two results came in under 90% of label, both on certificates the vendors published themselves. These are results vendors and labs chose to publish, not a random sample of what is sold.

PT-141 at a glance.

What it isBremelanotide, a cyclic seven-amino-acid melanocortin receptor agonist
US approvalVyleesi, NDA 210557, approved 21 June 2019
Approved usePremenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Label on every certificate10 mg
Lab results we mirror33, from 5 sources, 26 client names
Test dates19 Mar 2025 to 25 Jun 2026
Median fill109.9% of label (32 results)
Lowest / highest fill81.5% / 148.8%
Under label / under 90%5 / 2 of 32
Median purity99.88% (33 results), lowest 99.13%
Graded fail / identity failed0 / 0
Carry an endotoxin result25 of 33
Carry a sterility screen15 of 33
FDA warning letters, 24 Aug 2026PT-141 named in all five

Sources for each row are in the sections below.

What PT-141 is.

The current Vyleesi label describes bremelanotide acetate as "a synthetic, cyclic heptapeptide" with molecular weight 1025.2 (free base). It calls the drug a melanocortin receptor agonist that activates several receptor subtypes without selectivity, and states that the mechanism by which it works in HSDD is unknown (DailyMed, Vyleesi label). Particle Peptides' certificate prints the sequence as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH.

Bremelanotide is related to melanotan 2, a broader melanocortin agonist with no approval. The two are different molecules, and a certificate for one does not cover the other.

We make no claim about what PT-141 does in people.

The US regulatory record.

DateEventSource
21 Jun 2019FDA approves Vyleesi (bremelanotide) injection, NDA 210557, as a new molecular entity; prescription onlyDrugs@FDA, NDA 210557
24 Aug 2026FDA sends warning letters to five research-peptide vendors; PT-141 is named in all fiveOur letters report
22 Oct 2026Latest Vyleesi labeling supplement listed on Drugs@FDA (patient package insert)Drugs@FDA, NDA 210557

The approval. Drugs@FDA lists the application holder as Cosette. The label limits the approved use: Vyleesi "is not indicated for the treatment of HSDD in postmenopausal women or in men", and is not indicated to enhance sexual performance. Its warnings include a transient increase in blood pressure with a reduction in heart rate, and nausea.

What that means for a research vial. The approval covers the Vyleesi product, made and tested under its application. A vial sold as "research PT-141" is outside it, whatever the certificate shows. Bremelanotide is not a controlled substance, and federal law does not make possessing it a crime, though state law can differ. Selling it for human use outside the approval is selling an unapproved drug, and a "research use only" label does not change that when a shop markets it for people. Our peptide legality tool keeps the record for PT-141.

The letters. Each of the five FDA warning letters dated 24 August 2026, to Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners and Tex Peptides, lists PT-141 among the products FDA cited. Our report on the letters and the FDA enforcement timeline have the detail. One of the 28 Kovera certificates below is for Peptide Partners.

What 33 public lab results show.

We pooled PT-141 results from the six certificate sources in our 2,087-result purity study, with the same rules for duplicates. Five sources carried PT-141; Injectify had none. We left out one Janoshik catalogue entry with no readable result.

SourceResultsData as ofMedian fillMedian purityTest dates
Kovera Labs public verifier28certificates re-read 10 Nov 2026110.4%99.91%Feb to Jun 2026
Janoshik public tests1snapshot of 30 Jun 2026114.3%99.90%Apr 2026
Ascension Peptides COA page (MZ Biolabs)2mirrored 26 May 202681.5% (1 result)99.57%Oct 2025, Feb 2026
Particle Peptides COA download (Apigenex)1mirrored 21 May 202685.0%99.13%Mar 2025
Swiss Chems test page1mirrored 26 May 202699.6%99.80%Mar 2026
All sources33109.9% (32)99.88% (33)Mar 2025 to Jun 2026

We last re-read the Kovera certificates on 10 November 2026, and our Janoshik mirror stops at its 30 June 2026 snapshot. We do not count anything published after those dates.

The pool carries 26 distinct client names, three of them email addresses, which we do not print. One lot, PT100526, appears on four Kovera certificates issued to four different clients on 13 May 2026. We count it twice, because the original prints a single-vial figure (10.97 mg) and the three copies a batch average (11.00 mg). Our shared-certificate report covers that lot. Our October study counted 34 PT-141 results. The difference is one Swiss Chems certificate published as two images, which we count once here. The median fill, purity and fail count are the same.

Fill: how much is in the vial.

Fill bandResultsShare of 32
Under 90% of label26.3%
90% to 100%39.4%
100% to 105%00%
105% to 110%1134.4%
110% to 115%515.6%
115% to 120%825.0%
Over 120%39.4%

The middle half of results sits between about 107% and 118% of label. The median across all fill results in the wider study was 109.6%, close to PT-141's.

The two results under 90%. Both are certificates the vendor published on its own site:

  • Ascension Peptides' MZ Biolabs certificate for lot 28-01260229 (dated February 2026) reports 8.15 mg in a 10 mg vial, 81.5% of label, at 99.47% purity, and grades the result a pass (certificate page). A later Kovera certificate for an Ascension Peptides lot, 28-05260628, reports 10.96 mg (KVR-2026-E6F074, 23 May 2026).
  • Particle Peptides' Apigenex certificate for batch 2025233 (19 March 2025) reports 8.5 mg, or a peptide content of 85.4%, at 99.13% purity, with identity confirmed and endotoxin negative.

A vendor that publishes its own low result is showing more than one that leaves it off. We read both as what the certificates print, not as a finding about any other lot.

The other three under label are 9.24 mg on a Kovera certificate for Prevail Peptides (KVR-2026-706EF1, 7 May 2026), 9.81 mg for Glacier Aminos (KVR-2026-4287AA, 30 April 2026) and 9.96 mg on Swiss Chems' certificate for lot CY1008 (March 2026). No Kovera result was under 92.4% of label.

The highest is 14.88 mg in a vial labelled 10 mg (148.8%), on a Kovera certificate with no client name and lot PT0001 (KVR-2026-78FEF1, 15 February 2026). Next are Peptide Partners at 13.10 mg (KVR-2026-28597D, 25 June 2026) and 12.61 mg on a certificate whose client name is a personal email address (KVR-2026-EE0D08, 25 April 2026).

What "pass" means on net content. As served on 10 November 2026, 12 of the 28 Kovera PT-141 certificates print a net-content specification of "10mg ± 10%", report more than 11 mg, and mark net content a pass. Two more print "~10mg" as the specification. Overfill leaves no peptide missing, but the grade does not follow the printed specification. Our certificate revisions report tracks the one PT-141 certificate whose figures changed after publication, KVR-2026-AEC9DB.

Purity.

Purity here is the chromatography figure the certificate prints: HPLC on most, UPLC on Particle's.

Purity bandResultsShare of 33
99.5% or higher3090.9%
99% to 99.5%39.1%
Under 99%00%

The three lowest are Particle Peptides at 99.13% (March 2025), a Kovera certificate for Ascension Peptides at 99.26% (KVR-2026-E6F074) and Ascension's own February 2026 certificate at 99.47%. The highest is 99.98%, for Glacier Aminos (KVR-2026-1BC9ED, 5 March 2026). One Ascension certificate (lot 28-03250428, October 2025) prints purity and identity but no amount, so it counts here and not in the fill table.

Fails and identity.

No result in the 33 was graded a fail, and every certificate that reports identity confirmed PT-141. Swiss Chems' certificate confirms identity by mass spectrometry on a second page; we count the two pages as one result.

Endotoxin, sterility and heavy metals.

TestCertificates carrying itResult
Endotoxin25 of 33 (24 Kovera, 1 Particle)All pass; Kovera against "≤0.5 EU/mL", 18 printing the result as under 0.10 EU/mL; Particle negative at 5 EU/mg sensitivity
Microbial sterility screen15 of 33 (all Kovera)All "No Growth"; most labelled a rapid sterility test
Heavy metals17 of 33 (all Kovera)15 print arsenic, cadmium, lead and mercury negative; 2 link a separate heavy-metals report
Fentanyl screen2 of 33 (both Kovera)Not detected

The other eight results (the Janoshik, Ascension and Swiss Chems certificates and four Kovera ones) carry none of these. An endotoxin limit per millilitre also depends on how much liquid the lab used. Our endotoxin guide works through what a figure means per vial.

The bias you have to read first.

Every result here is one that a vendor or buyer chose to send to a lab, and one the lab or vendor chose to publish. Kovera and Janoshik publish fails next to passes, but the client still decides which vials reach them, and a vendor with a bad certificate can leave it off its own page. Zero fails in 33 is a statement about the published record, not a failure rate for PT-141 on the market.

The record is also small and concentrated: 28 of 33 results are Kovera certificates from a 19-week window in 2026, and only one is from Janoshik. One result moves the fill median by a fraction of a point. Read the tables as a description of 33 certificates, not a forecast for the next vial.

What you can and cannot conclude.

You can concludeYou cannot conclude
Most published PT-141 vials on this record held more than their 10 mg labelThat any other vial holds its label
Two vendor-published certificates show a vial under 90% of labelThat any other lot from those vendors is short
Purity was above 99% on every result with a figureThat the vial is free of endotoxin or microbes, unless its own certificate shows those tests
Every certificate that reports identity confirmed PT-141That a research vial is equivalent to Vyleesi
Kovera marked 12 over-spec fills a pass (as served 10 Nov 2026)That a "pass" on net content means the amount is close to label

Prices.

Our price index holds no PT-141 listing in its build of 17 November 2026, so we publish no price per mg for it.

How to read a PT-141 certificate.

  1. Check the name and the label. The certificate should name PT-141 or bremelanotide and the same label amount and lot as the vial.
  2. Read the amount, not only the grade. A result can be graded a pass at 81.5% of label or at 148.8%. Divide the measured mg by the label.
  3. Read the specification next to the result. "10mg ± 10%" with 11.9 mg measured and a pass tells you the grade does not follow the printed specification.
  4. Look for the panels that are not there. Endotoxin and sterility are separate tests. Eight of the 33 certificates here carry no endotoxin result.
  5. Verify at the lab and match the lot. Use Kovera's verifier or Janoshik's, and our guides to verifying a peptide COA and verifying a Janoshik COA. A certificate covers one tested sample.

Our methodology page explains how we read and score lab records.

What we read, and what we did not.

We read 33 PT-141 results in our mirrors of Kovera Labs' public verifier (certificates re-read 10 November 2026), Janoshik's public test listing (30 June 2026 snapshot), and the certificate pages of Ascension Peptides (26 May 2026), Particle Peptides (21 May 2026) and Swiss Chems (26 May 2026). We read the Drugs@FDA record for NDA 210557 and the current Vyleesi label on DailyMed on 19 November 2026, and the five FDA warning letters dated 24 August 2026 as covered in our letters report. We did not test any vial, and we do not publish the client email addresses printed on some certificates.

Sources.

Frequently asked

What is PT-141?

PT-141 is the development code for bremelanotide, a synthetic cyclic heptapeptide. The Vyleesi label describes it as a melanocortin receptor agonist that activates several receptor subtypes without selectivity. Every PT-141 certificate in the public record we mirror is for a vial labelled 10 mg.

Is PT-141 the same as Vyleesi?

The molecule is the same: bremelanotide is the active ingredient of Vyleesi (NDA 210557, approved 21 June 2019). The product is not. A research vial is not made, tested or labelled under that approval, and a certificate for one says nothing about the other.

Are PT-141 vials underfilled?

Most published results are over label. Of 32 results with a measured amount, the median was 10.99 mg in a 10 mg vial (109.9%). Five were under label and two under 90%: Ascension Peptides' own certificate for lot 28-01260229 (8.15 mg, 81.5%, February 2026) and Particle Peptides' own certificate for batch 2025233 (8.5 mg, 85.0%, March 2025). The lowest of 28 Kovera results was 9.24 mg (92.4%).

How pure is PT-141 on the public record?

Across 33 results with a purity figure, the median was 99.88%. None was under 99%; the lowest was 99.13%, on Particle Peptides' 2025 certificate, which uses UPLC rather than HPLC.

Do PT-141 certificates test for endotoxin or sterility?

Some do. 25 of the 33 carry an endotoxin result (24 Kovera, one Particle), 15 a microbial sterility screen and 17 a heavy-metals result or report, all passes. The Janoshik, Ascension and Swiss Chems certificates in the pool carry none of these.

Is PT-141 legal to buy in the US?

Bremelanotide is a prescription drug in the US, sold as Vyleesi. It is not a controlled substance, and federal law does not make possessing it a crime; state law can differ. Selling it for human use outside the approval is selling an unapproved drug, and all five FDA warning letters to peptide vendors dated 24 August 2026 list PT-141 among the products cited.

Did vialaudit test any PT-141 vials?

No. We placed no orders and sent no samples to a lab. Every figure on this page comes from certificates that labs or vendors published, as mirrored by us on the dates given.

More from the desk

ALL ARTICLES →
THE ROUNDUP · MONTHLY

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 SUBSCRIBERS·0 SPONSORED ITEMS·11 ISSUES SINCE LAUNCH